Obesity Patents (Class 514/909)
-
Patent number: 7271153Abstract: The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 and X3 independently represent N or CH; X2 represents N or CR2; X4 represents N or CR3; and with the proviso that one or two of X1, X2, X3 and X4 represent N; R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkoxy-substituted (lower alkyl) group, a lower alkoxy-substituted (lower alkoxy) group, a lower alkoxy(lower alkoxy)-substituted (lower alkyl) group, a cyclic lower alkyl group, a halo(lower alkyl) group or a group represented by the general formula: HO-A- wherein A represents a lower alkylene group, a lower alkyleneoxy group or a lower alkylenethio group; R2 represents a hydrogen atom, a halogen atom, a lower alkyl group, a cyclic lower alkyl group, a lower alkoxy group, an amino group, a (lower acyl)amino group, a mono(lower alkyl)amino group or a di(lower alkyl)amino group; and R3 represents a hydrogen aType: GrantFiled: June 17, 2002Date of Patent: September 18, 2007Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Toshihiro Nishimura, Hideki Fujikura, Nobuhiko Fushimi, Kazuya Tatani, Kenji Katsuno, Masayuki Isaji
-
Patent number: 7268161Abstract: The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: July 6, 2004Date of Patent: September 11, 2007Inventor: Martin C. Hinz
-
Patent number: 7229965Abstract: The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human growth hormone, for the manufacturing of a medicament useful for increasing insulin sensitivity in low dose therapy. The patient is preferably a normal subject, i.e. not growth hormone deficient patient and/or a non-obese patients. By low dose therapy is preferably meant less than 0.008 mg/kg/day, preferably 0.007 mg/kg/day or less, more preferably 0.005 mg/kg/day or less and most preferably 0.003 mg/kg/day or less. The therapy is preferably performed during short term treatment, preferably less than one month.Type: GrantFiled: January 21, 2004Date of Patent: June 12, 2007Assignee: Pharmacia ABInventor: David B Dunger
-
Patent number: 7223727Abstract: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.Type: GrantFiled: February 7, 2002Date of Patent: May 29, 2007Assignee: Serono Genetics Institute S.A.Inventors: Barbara Chicca, John Chicca, Blake Denison, Frances Yen-Potin, Bernard Bihain, Stephane Bejanin, Hiroaki Tanaka, Severin Jobert, Jean-Yves Giordano, Jean-Baptiste Dumas Milne Edwards
-
Patent number: 7214778Abstract: A glycoprotein extracted from the fruiting body of Grifola frondosa is demonstrated to have antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects, and has great potential as an active component for pharmaceuticals, dietary supplements or health food preparations to treat and/or prevent the above diseases. This invention is to provide the glycoprotein and its preparation method.Type: GrantFiled: January 22, 2004Date of Patent: May 8, 2007Assignee: Masaki ShirotaInventors: Cun Zhuang, Hirokazu Kawagishi, Harry G. Preuss
-
Patent number: 7211557Abstract: This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight.Type: GrantFiled: May 5, 2003Date of Patent: May 1, 2007Assignee: Eli Lilly and CompanyInventors: Richard DiMarchi, Suad Efendic
-
Patent number: 7199160Abstract: Antiobestic agents and health foods containing as the active ingredient substances having an effect of adsorbing bile acid in the digestive tract, an effect of inhibiting intestinal circulation or an effect of inhibiting the absorption of exogenous lipids typified by pharmaceutically acceptable anion exchange resins. In particular, antiobestic agents and health foods characterized by lowering body weight and/or visceral fat content without reducing food intake.Type: GrantFiled: October 9, 2001Date of Patent: April 3, 2007Assignee: Mitsubishi Pharma CorporationInventors: Kazuo Suzuki, Shigekazu Nakajima, Shinji Yano
-
Patent number: 7175859Abstract: A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. Such compositions have beneficial activity principally in controlling weight gain and obesity, especially in conjunction with chitosan or a chitosan derivative and an antioxidant such as vitamin C.Type: GrantFiled: August 29, 2000Date of Patent: February 13, 2007Assignee: Gateway Health Alliances, Inc.Inventor: Julius Enyong Oben
-
Patent number: 7160924Abstract: The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same.Type: GrantFiled: July 18, 2003Date of Patent: January 9, 2007Assignees: The General Hospital Corporation, Amgen, Inc.Inventors: Olaf B. Kinstler, David L. Ladd, Mikahil I. Papisov
-
Patent number: 7153877Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: December 9, 2004Date of Patent: December 26, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7138107Abstract: The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical composition comprising an effective amount of a calcium channel blocker to the nasal mucosa, as well as screening methods for drugs to be used in treating obesity or associated disorders.Type: GrantFiled: February 18, 2003Date of Patent: November 21, 2006Assignee: Compellis PharmaceuticalsInventors: Christopher P. Adams, James Flynn
-
Patent number: 7122209Abstract: Oral compositions containing an effective amount of a tungsten compound (VI), preferably a tungstate salt, more preferably sodium tungstate (Na2WO4), are useful in controlling obesity/overweightness in non-diabetic mammals, including humans. The anti-obesity effect of sodium tungstate dihydrate in rats has been determined in a cafeteria-diet-induced obesity model. Said obese rats are good models of obese, non-diabetic mammals, including humans. The prophylactic, therapeutic and/or cosmetic treatment resulting from this invention is surprising. It provides advantages such as effectiveness, lack of toxicity and relatively low price in comparison with other treatments in prior art. Hence, the oral compositions according to the invention are useful for the treatment of obesity/overweightness in non-diabetic mammals, including humans.Type: GrantFiled: May 16, 2002Date of Patent: October 17, 2006Assignee: Quimica Farmaceutica Bayer S.A.Inventors: Ramon Gomis De Barbara, Marc Claret Carles, Joan-Josep Guinovart Cirera, Josefa Fernandez Alvarez
-
Patent number: 7119110Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: October 4, 2002Date of Patent: October 10, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7115575Abstract: The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.Type: GrantFiled: July 28, 2005Date of Patent: October 3, 2006Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Hideki Fujikura, Toshihiro Nishimura, Kenji Katsuno, Masahiro Hiratochi, Akira Iyobe, Minoru Fujioka, Masayuki Isaji
-
Patent number: 7101838Abstract: The present invention provides for a method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent accelerated atherosclerosis in the subject. The present invention also provides for a method to prevent a macrovessel disease in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent macrovessel disease in the subject.Type: GrantFiled: August 5, 1997Date of Patent: September 5, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: David Stern, Ann Marie Schmidt
-
Patent number: 7094763Abstract: This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.Type: GrantFiled: July 30, 2004Date of Patent: August 22, 2006Assignee: Janssen Pharaceutica, N.V.Inventors: Philip Rybczynski, Maud Urbanski, Xiaoyan Zhang
-
Patent number: 7067498Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.Type: GrantFiled: May 29, 2002Date of Patent: June 27, 2006Assignee: Abbott LaboratoriesInventors: Bryan W. Wolf, Bruce B. Blidner, Keith A. Garleb, Chron-Si Lai, Timothy W. Schenz
-
Patent number: 7056892Abstract: The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.Type: GrantFiled: July 27, 2005Date of Patent: June 6, 2006Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Hideki Fujikura, Toshihiro Nishimura, Kenji Katsuno, Masahiro Hiratochi, Akira Iyobe, Minoru Fujioka, Masayuki Isaji
-
Patent number: 7048917Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.Type: GrantFiled: November 22, 2000Date of Patent: May 23, 2006Assignee: Genzyme CorporationInventors: Thomas Jozefiak, Stephen Randall Holmes-Farley, W. Harry Mandeville, III, Chad Cori Huval, Venkata R. Garigapati, Keith K. Shackett, Danny Concagh
-
Patent number: 6989165Abstract: The present invention relates to a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of plant Gentiana kurroo of concentration ranging between 2–5 wt. %, Murraya koenigii of concentration ranging between 8–15 wt %, Allium sativum of concentration ranging between 2–4 wt %, Zingiber officinalis of concentration ranging between 2–5 wt %, Amorphophallus campanulatus of concentration ranging between 1–10%, and pharmaceutically acceptable additive(s); a process for the preparation of the said synergistic pharmaceutical composition; and also, a use of the said composition for treating hyperlipidemia, atherosclerosis, and obesity.Type: GrantFiled: March 31, 2004Date of Patent: January 24, 2006Assignee: Council of Scientific and Industrial ResearchInventors: Palpu Pushpangadan, Shanta Mehrotra, Chandana Venkateswara Rao, Sanjeev Kumar Ojha, Govindarajan Raghavan, Guntupalli Madan Mohana Rao, Sreedevi Padmavathi
-
Patent number: 6989367Abstract: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.Type: GrantFiled: November 1, 2002Date of Patent: January 24, 2006Assignee: Genset S.A.Inventors: Joachim Fruebis, Mary Ruth Erickson, Frances Yen-Potin, Bernard Bihain
-
Patent number: 6972283Abstract: The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 represents a group represented by the general formula: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of diabetes, diabetic complications or obesity, and to pharmaceutical compositions comprising the same and intermediates thereof.Type: GrantFiled: January 20, 2004Date of Patent: December 6, 2005Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Hideki Fujikura, Toshihiro Nishimura, Kenji Katsuno, Masahiro Hiratochi, Akira Iyobe, Minoru Fujioka, Masayuki Isaji
-
Patent number: 6960300Abstract: Aqueous solutions of diterpenes such as Forskolin, its congeners, analogs and derivatives, up to approximately 6% concentration, are prepared using suitably substituted cyclodextrin as a solubilizing agents. In the absence of cyclodextrin, some diterpenes such as Forskolin are soluble in water only to concentrations of about 0.001%. Such aqueous solutions find applications in topical and systemic use, as pharmaceutical, cosmeceutical, nutraceutical preparations containing diterpenes such as Forskolin and congeners.Type: GrantFiled: September 8, 2003Date of Patent: November 1, 2005Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Arvind Kumar, Kalyanam Nagabhushanam, Subbalakshmi Prakash
-
Patent number: 6896909Abstract: The invention relates to formulations for the topical treatment of disorders with a bioenergetic basis, which contain a suspension obtainable by treating one or more iron ores with aqueous solutions having pH values of between 4 and 8. These formulations will be applied directly to the acupuncture points corresponding to the meridians involved in the conditions to be treated.Type: GrantFiled: May 7, 2002Date of Patent: May 24, 2005Assignee: GeoMedical S.r.l.Inventor: Mauro Fanelli
-
Patent number: 6875428Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: GrantFiled: February 5, 2003Date of Patent: April 5, 2005Assignee: Genzyme CorporationInventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
-
Patent number: 6863904Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.Type: GrantFiled: October 14, 2003Date of Patent: March 8, 2005Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles Balzer
-
Patent number: 6861073Abstract: The present invention provides a method of treating obesity in mammals, particularly humans. The method comprises the step of administering a dietary supplement that includes about 25 mg to about 10 g calcium carbonate precipitate; about 25 mg to about 10 g coral calcium; about 10 mg to about 10 g magnesium carbonate; about 10 mg to about 5 g potassium carbonate; a plurality of vitamins, including Vitamin C; and a plurality of amino acids.Type: GrantFiled: April 11, 2003Date of Patent: March 1, 2005Inventor: Paul Ling Tai
-
Patent number: 6852342Abstract: The present invention relates to a process of providing an extract containing at least one simmondsin compound. The extract is provided from jojoba plant, and used as a dietary supplement for use in a weight control regiment in humans. The present invention also provides a method of treating an overweight human in need of such treatment, and comprises administering a therapeutically effective amount of such an extract.Type: GrantFiled: March 26, 2002Date of Patent: February 8, 2005Assignees: Avoca, Inc., ChromaDex, Inc.Inventors: Richard King Teague, Samuel Leonard Tynch, Frank Louis Jaksch, Jr., Richard Theodore Maier, Jr.
-
Patent number: 6849609Abstract: The present invention is directed towards a method and composition for controlled release acarbose formulations. The method and composition disclosed herein combine acarbose and a sustained release matrix. The administration of acarbose alone has been shown to be useful in the treatment of diabetes. Although the initial studies conducted herein were conducted with a delayed release formulation that allowed partial sustained release administered to stimulate sustained release, all indicators from the present invention suggest the formulation of acarbose in a sustained release formulation would have heretofore unexpected benefits. In a sustained release formulation, the ingredient(s) would be a shaped dosage unit having a sustained and regular release of acarbose throughout the small intestine where carbohydrates as a simple sugar are absorbed.Type: GrantFiled: April 10, 2001Date of Patent: February 1, 2005Inventor: James U. Morrison
-
Patent number: 6844021Abstract: The oil or fat composition of the invention contains a monoacylglycerol and/or a diacylglycerol in a total amount of 5-100 wt. % and which exhibits an index of stability against oxidation (induction time as measured through a Rancimat test conducted at 100° C.) of 7 or higher, wherein the monoacylglycerol and/or the diacylglycerol contain, as fatty acid constituents, ?3 unsaturated fatty acids in amounts of 15-90 wt. %. Through ingestion thereof in a small amount without drastically changing the person's lifestyle, the highly harmless oil/fat composition of the present invention provides effects for reducing and preventing accumulation of body fat, for reducing and preventing accumulation of visceral fat, and for prevention and treatment of obesity; and exerts an excellent prevention and treatment effect on life-style related diseases through long-term ingestion. Thus, the composition of the present invention is useful for foods, pharmaceuticals and pet food or feed.Type: GrantFiled: April 26, 2002Date of Patent: January 18, 2005Assignee: Kao CorporationInventors: Shin Koike, Takatoshi Murase, Tadashi Hase
-
Patent number: 6831105Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: November 26, 2002Date of Patent: December 14, 2004Assignee: Esperion Therapeutics, Inc.Inventor: Jean-Louis Henri Dasseux
-
Patent number: 6825209Abstract: Compounds are provided that are amide analogs of SR141716A having unique CB1 receptor selectivity and providing WIN sparing binding characteristics, pharmaceutical compositions containing the compounds and their use in a method of treatment of CB1 receptor related disorders, such as obesity, schizophrenia, memory dysfunction and marijuana abuse.Type: GrantFiled: April 15, 2002Date of Patent: November 30, 2004Assignee: Research Triangle InstituteInventors: Brian F. Thomas, Herbert H. Seltzman, Maria Elena Y. Francisco
-
Patent number: 6815417Abstract: A method for treating obesity includes administering to humans or animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition. Stanniocalcin has an excellent activity of inhibiting the differentiation and maturation of adipocytes and therefore is useful as a drug for treating obesity.Type: GrantFiled: May 17, 2001Date of Patent: November 9, 2004Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Masaaki Goto, Akihiro Tomoyasu, Kyoji Yamaguchi, Masahiko Kinosaki, Nobuaki Nakagawa
-
Patent number: 6797283Abstract: The present invention is directed to a multilayered dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a multilayer core, often bilayer, formed of polymer matrices that swell upon contact with the fluids of the stomach. At least one layer of the multilayered dosage form includes an active agent. A portion of the polymer matrices are surrounded by a band of insoluble material that prevents the covered portion of the polymer matrices from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.Type: GrantFiled: December 22, 1999Date of Patent: September 28, 2004Assignee: Alza CorporationInventors: David E. Edgren, Francisco Jao, Patrick S. -L. Wong
-
Patent number: 6780851Abstract: A composition is disclosed suitable for the prevention and/or treatment of disorders due to abnormal lipid metabolism, such as hypercholesterolaemia, atherosclerosis, hyperlipidaemia and obesity, and which can therefore take the form of a dietary supplement or of an actual medicine, comprising as characterising active ingredients: (a) propionyl L-carnitine or a pharmacologically acceptable salt thereof, and (b) chitosan or its derivatives and congeners.Type: GrantFiled: May 20, 2002Date of Patent: August 24, 2004Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Claudio Cavazza
-
Patent number: 6764692Abstract: A method of treating laminitis in a horse is disclosed, comprising administering to the horse a naturally chelated trace mineral composition; promoting healthy skin, hair and hoof tissue. A method of reducing dietary intake is also disclosed, comprising administering to a horse in need thereof, effective amounts of a naturally chelated trace mineral composition. A method of preparing the chelated trace mineral composition from ocean seabed rock is further disclosed, as well as the chelated trace mineral composition.Type: GrantFiled: August 27, 2002Date of Patent: July 20, 2004Inventor: Carlos Cortelezzi
-
Patent number: 6759437Abstract: The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, Cysteine, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: September 6, 2001Date of Patent: July 6, 2004Inventor: Martin C. Hinz
-
Patent number: 6759049Abstract: The invention concerns the field of pharmaceutics and dietetics. More particularly, the invention concerns pharmaceutical and/or dietetic mushroom-based compositions, characterised in that they contain one or several edible mushrooms with therapeutic properties and chitosan.Type: GrantFiled: February 25, 2001Date of Patent: July 6, 2004Assignee: Medecine Information Formation S.A.Inventor: Bruno Donatini
-
Patent number: 6734160Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone.Type: GrantFiled: May 21, 1999Date of Patent: May 11, 2004Assignee: The Rockefeller UniversityInventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
-
Patent number: 6733793Abstract: An orally administered, novel dietary supplement or therapeutic composition capable of insulin-like activity in animals, preferably humans, is provided. Contained in the composition are therapeutically effective amounts of vanadyl sulfate, alpha-lipoic acid, taurine, and chromium carnitine. The composition is preferably orally administered on a daily basis for at least about 4 weeks and can be used by normal, healthy individuals as well as diabetics.Type: GrantFiled: June 4, 2002Date of Patent: May 11, 2004Assignee: MetaProteomics, LLCInventors: Linda M. Pacioretty, John G. Babish
-
Patent number: 6723737Abstract: The invention discloses methods for the chronic administration of adenosine, which contrary to the acute delivery of the drug by injection or infusion, acts in desensitizing adenosine receptors towards the action of adenosine. The methods and oral compositions of adenosine triphosphate (ATP), which is degraded to adenosine in vivo, can be used in the treatment of disorders and diseases that are therapeutically targeted by agonists or antagonists of adenosine receptors. One example is the stimulation of lipolysis in achieving weight loss in humans and in the treatment of obesity.Type: GrantFiled: April 22, 2002Date of Patent: April 20, 2004Inventor: Eliezer Rapaport
-
Patent number: 6716436Abstract: A cosmetic composition for slimming which includes, in combination with a cosmetically acceptable excipient, at least one compound having the formula (I) where R1 is a group bound by a peptidic bond and selected from the group consisting of a hydrogen atom, a hydroxyl group, an acyl group, acyloxy group and a substituted or unsubstituted aminoacid; R2 is a group bond by a peptidic bond and selected from the group consisting of a hydroxyl group, an amine group, an alkoxy group, an alkylamine group, a silyloxy group or a substituted or unsubstituted aminoacid; and n is 3 or 4.Type: GrantFiled: June 16, 2000Date of Patent: April 6, 2004Assignee: Exsymol S.A.M.Inventor: Marie-Christine Seguin
-
Patent number: 6706255Abstract: Liquid pharmaceutical compositions comprising at least one thyroid hormone, ethanol, a pH adjusting agent, and water are disclosed. The compositions may be delivered by a metered dosage delivery system such as an aerosol or pump-action spray, and are useful in the treatment of disorders associated with an impairment of thyroid hormone function in animals including human beings.Type: GrantFiled: September 13, 2002Date of Patent: March 16, 2004Assignee: Abbott GmbH & Co., KGInventors: Jeffrey Dickinson, Karrar Ahmad Khan, John Neville Hague, Alan Smith
-
Patent number: 6696414Abstract: The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human growth hormone, for the manufacturing of a medicament useful for increasing insulin sensitivity in low dose therapy. The patient is preferably a normal subject, i.e. not growth hormone deficient patient and/or a non-obese patients. By low dose therapy is preferably meant less than 0.008 mg/kg/day, preferably 0.007 mg/kg/day or less, more preferably 0.005 mg/kg/day or less and most preferably 0.003 mg/kg/day or less. The therapy is preferably performed during short term treatment, preferably less than one month.Type: GrantFiled: March 13, 2001Date of Patent: February 24, 2004Assignee: Pharmacia ABInventor: David B. Dunger
-
Patent number: 6660777Abstract: The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.Type: GrantFiled: August 29, 2001Date of Patent: December 9, 2003Inventor: Martin C. Hinz
-
Patent number: 6656473Abstract: Compositions are described comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, preferably squash seeds, and, optionally, a carbohydrate source provided in an amount capable of facilitating transport of in vivo generated tryptophan across the blood brain barrier. Also described are dietary supplements, foods and beverages comprising the composition of the invention to induce sleep or provide tryptophan supplementation to individuals in need thereof.Type: GrantFiled: July 11, 2001Date of Patent: December 2, 2003Inventors: Susan P. Hudson, Craig J. Hudson
-
Patent number: 6652839Abstract: A gum, lollipop and lozenge having at least two separate components, the first component having desirable taste characteristics and the second component having a diet control composition incorporated therein.Type: GrantFiled: December 10, 2002Date of Patent: November 25, 2003Inventor: Jack Barreca
-
Patent number: 6627206Abstract: An apparatus and method for treating obesity and for delivering time-released medicaments is described and which includes a plurality of space-filling portions which are sized to be received within a human patient's body and which come together in a patient's body to form a structure which provides therapeutic benefit to the patient. In the method of the present invention, the method includes providing a plurality of space-filling portions which are sized to be received within the patient's body; and inserting the space-filling portions into the body of the patient and wherein the respective space-filling portions come together following insertion into the body to form a structure providing therapeutic benefit to the patient.Type: GrantFiled: July 25, 2001Date of Patent: September 30, 2003Inventor: Greg A. Lloyd
-
Patent number: 6608064Abstract: The present invention is directed to the use of certain pyrido[1,2-a]-pyrazine derivatives, also described as bis-azabicyclic compounds and defined by the formula (I) herein, in the treatment of Parkinson's disease, attention deficit hyperactivity disorder and microadenomas in mammals, and to related compositions.Type: GrantFiled: May 3, 2001Date of Patent: August 19, 2003Assignee: Pfizer IncInventors: Stafford McLean, Stevin H. Zorn, Elisa R. Jackson
-
Patent number: 6596288Abstract: The present invention relates to the use of sterols derived from a plant or algae extract as the active principle of a cosmetic composition for combating adiposity. Said sterols are, for example, at least one of the three following sterols: campesterol, beta-sitosterol or stigmasterol.Type: GrantFiled: November 30, 2001Date of Patent: July 22, 2003Assignee: Codif International SAInventors: Antoine Gedouin, Romuald Vallee, Pierre-Yves Morvan